Key result
Planned RCT evaluates cardiovascular ultrasound therapy for hsCRP effects in post-PCI CAD patients.
Why the study?
Cardiovascular ultrasound therapy has shown effectiveness and safety in refractory angina, but relevant clinical studies and clinical evidence in CAD after PCI are lacking.
Does cardiovascular ultrasound therapy added to usual practice reduce high-sensitivity C-reactive protein in patients with coronary artery disease after percutaneous coronary intervention?
RCT (n=200)
Double-blind
Stratified block randomization (1:1)
Yes
Does cardiovascular ultrasound therapy added to usual practice reduce high-sensitivity C-reactive protein in patients with coronary artery disease after percutaneous coronary intervention?
This study protocol describes a multicenter RCT to evaluate whether cardiovascular ultrasound therapy improves inflammatory markers and rehabilitative outcomes in patients with CAD after PCI.
Answers are grounded in this paper and cite their sources.
Planned RCT will test ultrasound therapy on hs-CRP post-PCI; leaves open its efficacy and safety until results are reported.
BACKGROUND: Coronary artery disease (CAD) is a leading cause of mortality and disability, placing heavy burdens on healthcare systems. Although cardiovascular ultrasound therapy has demonstrated effectiveness and safety in improving refractory angina, relevant clinical studies are rare and clinical evidence is lacking. METHODS AND DESIGN: This is a prospective, parallel-group, randomized controlled trial. We enrolled 200 patients with coronary artery disease who had undergone percutaneous coronary intervention (PCI) and randomized them into two groups. The intervention group will be given usual-practice plus cardiovascular ultrasound therapy intervention and the control group will be given only usual-practice intervention. After 20 treatments with cardiovascular ultrasound therapy, high-sensitivity C-reactive protein in serum will be used as the primary outcome measures. The following will be used in determining secondary outcomes: indicators of serum myocardial injury, blood lipid levels, markers of endothelial function, inflammatory factors, hemodynamic indicators, echocardiography, ultrasound examination for carotid plaques, 6-minute walk test, short-term variability in heart rate, and mental health assessment. The researchers plan to test the outcome indicators at multiple time points. Statistical analyses will be performed using SPSS version 26 statistical software (IBM, Armonk, NY). DISCUSSION: This is the first clinical study of the rehabilitative efficacy of cardiovascular ultrasound therapy in the treatment of CAD after PCI. Clinical recovery currently depends mainly on modalities such as medication, exercise, and nutritional therapy; therefore, cardiovascular ultrasound therapy, as a new mode of therapy, might become a major advance in the treatment of CAD after PCI. TRIAL REGISTRATION: ClinicalTrials.gov NCT06640400.
No takes yet. Share an insight, caveat, or question.
He et al. (2025) conducted an RCT in Coronary artery disease after percutaneous coronary intervention (n=200). Cardiovascular ultrasound therapy vs. Sham stimulation (simulator) was evaluated on High-sensitivity C-reactive protein (hsCRP) levels in peripheral serum after 20 treatments. Cardiovascular ultrasound therapy will be evaluated for its effect on high-sensitivity C-reactive protein levels in a planned randomized controlled trial of 200 patients with coronary artery disease after percutaneous coronary intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: